Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Corcept Therapeutics (NQ: CORT ) 30.97 +0.58 (+1.91%) Streaming Delayed Price Updated: 10:58 AM EDT, Jun 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Corcept Therapeutics < Previous 1 2 3 Next > Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions June 24, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) June 03, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) May 28, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update May 01, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Phase 4 CATALYST Trial April 29, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call April 24, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome April 22, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) April 15, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer April 08, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome April 01, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update February 15, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial February 15, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call February 08, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Appoints Roberto Vieira as President, Oncology January 29, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program January 08, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Court Finds Corcept Therapeutics’ Patents Not Infringed January 02, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update November 01, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Appoints Monica Tellado as President, Emerging Markets November 01, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH) October 26, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call October 25, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Inc. (NASDAQ: CORT) Sets New 52-Week High in Wednesday Session August 23, 2023 Via Investor Brand Network Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update August 02, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call July 26, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH) July 17, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer June 27, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update May 03, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call April 26, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Announces Final Results of Tender Offer April 05, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Announces Preliminary Results of Tender Offer April 03, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics Initiates CATALYST Clinical Trial March 28, 2023 From Corcept Therapeutics Incorporated Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.